ArticleJTO clinical and research reports2026
Safety and Efficacy of Bronchoscopic Pulsed Electric Field Ablation for Lung Cancer and Metastases.
Article in JTO clinical and research reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Local treatment options for progressive lung cancer or metastases located in the central or middle thirds of the lungs are limited, especially if progression occurs after radiation. In these patients, local thermal ablative therapies are fraught with complications. We investigated the safety and efficacy of local control in progressive lung and metastatic cancer by bronchoscopic pulsed electric field (PEF) ablation. Methods: We performed an analysis of prospectively collected data of all the patients with lung and metastatic cancer to the lungs treated by bronchoscopic PEF ablation at our institution between October 2024 and April 2025. Results: Seven lesions in six consecutive patients were treated by PEF ablation using robotic bronchoscopy with three-dimensional imaging. There were three patients with NSCLC, and three with colorectal cancer, urothelial cancer, and thyroid cancer. All patients had progressed on standard oncologic therapies, and five had received radiation to the lesions. The median tumor size was 2.1 cm (range, 1.1-4 cm), and all were located in the central or middle-thirds of the lungs. At the median follow-up of 9.7 (interquartile range, 5.4-10.1) months, four (57.1%) lesions increased in size, two (28.5%) decreased, and one (14.3%) resolved. The decreased size or resolution of lesions was seen in the three patients with NSCLC. No direct complications due to PEF were encountered, but one patient required prolonged mechanical ventilation related to anesthesia. Conclusions: In patients with lung cancer or lung metastases, bronchoscopic PEF ablation is safe and associated with mixed local control.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.